Tech Company Financing Transactions
Selecta Biosciences Funding Round
On 6/18/2014, Selecta Biosciences raised $9.4 million in funding from Bill & Melinda Gates Foundation and private investors.
Transaction Overview
Company Name
Announced On
6/18/2014
Transaction Type
Venture Equity
Amount
$9,350,000
Round
Undisclosed
Investors
Proceeds Purpose
Selecta continues to advance key immune activation programs, with newly-announced funding totaling $9.35 million from the Bill & Melinda Gates Foundation and NIH/NIDA.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
480 Arsenal St.
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
Selecta Biosciences, Inc. (NASDAQ: SELB) is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Werner Cautreels
Chief Financial Officer
John Leaman
Chief Medical Officer
Earl Sands
Chief Operating Officer
Lloyd Johnston
Chief Scientific Officer
Takashi Kishimoto
VP - Bus. Development
Stephen Smolinski
VP - General Counsel
David Abraham
Browse more venture capital transactions:
Prev: 6/18/2014: ClearCare venture capital transaction
Next: 6/18/2014: Other Machine venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs